HT
LXRX icon

Headlands Technologies’s Lexicon Pharmaceuticals LXRX Stock Holding History

Headlands Technologies’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Sell
167,198
-24,124
-13% -$47K 0.04% 462
2026
Q1 		$298K Buy
191,322
+55,209
+41% +$80.3K 0.03% 502
2025
Q4 		$157K Buy
136,113
+86,466
+174% +$119K 0.01% 609
2025
Q3 		$67K Buy
+49,647
New +$56.3K 0.01% 584
2024
Q1 		– Sell
-204
Closed -$312 – 1424
2023
Q4 		$312 Buy
+204
New +$243 ﹤0.01% 913

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Headlands Technologies's LXRX Position: Q2 2026 in Review

Headlands Technologies reduced its Lexicon Pharmaceuticals (LXRX) stake by 13% in Q2 2026, selling an estimated $47K and leaving 167,198 shares worth $401K. The position accounts for 0.04% of the portfolio, ranked #462.

Headlands Technologies first reported a position in LXRX in Q4 2023 and has held it in 5 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Headlands Technologies held 167,198 shares of Lexicon Pharmaceuticals worth $401K as of Q2 2026.
  • Headlands Technologies sold 24,124 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $47K.
  • Lexicon Pharmaceuticals made up 0.04% of Headlands Technologies's portfolio in Q2 2026, its #462 holding.
  • Headlands Technologies first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.